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Background: Patients with chronic urticaria (CU) are increasingly using information and
communication technologies (ICTs) to manage their health. What CU patients expect from ICTs
and which ICTs they prefer remains unknown. We assessed why CU patients use ICTs, which ones
they prefer, and what drives their expectations and choices.
Methods: In this cross-sectional study, 1841 patients across 17 countries were recruited at
UCAREs (Urticaria Centers of Reference and Excellence). Patients with CU who were >12 years old
completed a 23-item questionnaire.
Results: Most patients were interested in receiving disease information (87.3%), asking physicians
about CU (84.1%), and communicating with other patients through ICTs (65.6%). For receiving
disease information, patients preferred one-to-one and one-to-many ICTs, especially web
browsers. One-to-one ICTs were also the ICTs of choice for asking physicians about urticaria and
for communicating with other patients, and e-mail and WhatsApp were the preferred ICTs,
respectively. Many-to-many ICTs such as Facebook, Instagram, LinkedIn, and Twitter were least
preferred for all 3 purposes. Living in rural areas and higher education were linked to higher odds
of being interested in receiving disease information, asking physicians, and communicating with
patients through ICTs.
Conclusions: Most patients and especially patients with higher education who live in rural areas
are interested in using ICTs for their healthcare, but prefer different ICTs for different purposes, ie,versidad Espíritu Santo, Samborondón, Ecuador
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communicating with other patients. Our findings may help to improve ICTs for CU.
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WhatsAppINTRODUCTION much needed in clinical practice and improvingChronic Urticaria (CU) is a skin disorder char-
acterized by wheals, angioedema, or both, for
more than 6 weeks.1 The prevalence is
approximately 1%,2 and a recent systematic
review and meta-analysis reported an overall life-
time CU prevalence of 4.4% with Latin America
and Asia showing a higher point prevalence than
other regions.3 Importantly, CU persists for several
years and results, in many patients, in severely
impaired quality of life.4–7
Information and communication technologies
(ICTs) are used to communicate, manipulate, and
store data by electronic means. In healthcare, ICTs
support the exchange, knowledge transfer, elec-
tronic storage, and processing of information to
promote health and to manage chronic illnesses
and treat disease.8,9 These technologies include e-
mail, short message service (SMS), text messaging,
video chat (eg, Skype or Hangouts) and online
social media (eg, Facebook or Twitter) as well as
computing and mobile devices (smartphones
and tablets) that perform a wide range of
communication and information functions.10 With
ICTs, users have worldwide access and are
capable of immediate interaction with others,
which was previously not possible. Notably, over
the past decade, the usage of ICTs has increased
dramatically among adolescents and young
adults.11
Given their increasing usage, ICTs have become
critical for obtaining information from healthcare
providers (HCPs) and patients alike.12 Specifically,
these technologies have become central to patient
education, disease self-management, remote
monitoring of patients, and collection of daily
data,13,14 all of which have enhanced healthcare
by creating time/cost efficiencies, which areclinical outcomes.12,15 Previous studies found
WhatsApp, e-mail, and SMS to be the most
popular forms of electronic communication for
receiving and seeking information as well as
communicating with physicians among patients
with chronic diseases.16,17
Until very recently, it was largely unknown how
and why patients with CU use ICTs and their
expectations had not been assessed. To address
this knowledge gap, the global network of Urti-
caria Centers of Reference and Excellence
(UCAREs)18 performed an international study
and reported first results.19 Specifically, we
showed that virtually all CU patients included
had access to ICTs and very often used these
on a daily basis, mostly on a one-to-one and
one-to-many basis. The use of ICTs for obtaining
health and CU-specific information was
extremely high in all countries analyzed, with
web browsers being the preferred ICT platform.
These findings were not a surprise given the
high burden of CU; patients seek knowledge
about CU and want to know about its causes,
course, possible trigger factors, and available
treatment options, as well as prognosis. More-
over, this need is mirrored by the fact that CU
patient-physician consultations are particularly
long and frequent.15
Here, we report on additional study outcomes,
focusing on why patients with CU use ICTs, which
ones they prefer when retrieving information, and
what drives their expectations and choices. Specif-
ically, we assessed their interest in and preference
for ICTs (1) to receive disease information, (2) to ask
physicians about urticaria, and (3) to communicate
with other CU patients. We also aimed to identify
characteristics of those interested/not interested in
ICT usage for these purposes.
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Study design and population
The design and conduct of this study have been
previously described in detail.19 Briefly, this was an
anonymous, cross-sectional survey study (see
questionnaire in the supplement). Here, we
included additional patients totaling 1841 from
primary healthcare centers, university hospitals,
and specialized clinics (either public or private)
that belong to the UCARE network. The healthcare
facilities involved were located in Germany,
Argentina, Brazil, China, Denmark, Ecuador,
Greece, India, Iran, Peru, Poland, Russia, Spain,
Switzerland, the Netherlands, the United Arab
Emirates, and Turkey (Supplemental Table S1).
Patients were 12 years old and previously
diagnosed with chronic spontaneous urticaria
(CSU) or chronic inducible urticaria (CIndU) by a
physician. Those with other dermatological
diseases or intellectual disabilities were excluded.
Procedures
A 23-item questionnaire, designed, evaluated,
and reviewed by an expert panel of physicians
assessed the participants’ interest in (1) receiving
urticaria information, (2) asking physicians health-
related queries, and (3) communicating with
other urticaria patients through specific ICTs. The
questionnaire collected demographic (age,
gender, education level, living area, etc) and clin-
ical information (urticaria type, years with diag-
nosis, etc.) from each patient. Furthermore,
participants were asked to quantify their interest
using a scale (not interested, slightly interested,
moderately interested, very interested, and
extremely interested) and specific ICTs (blog or
forum, e-mail, Facebook, Instagram, LinkedIn,
Skype, SMS, Twitter, YouTube, web browser, and
WhatsApp; questionnaire is contained in the
Supplement).
Ethical considerations
This study was approved by the ethics commit-
tee “Comité de ética e Investigación en Seres
Humanos” (CEISH)”, Guayaquil, Ecuador (IRB
number HCK-CEISH-19-0059) and by a committee
for each participating UCARE center. Eachparticipant provided consent to completion of the
anonymous survey, and confidentiality was main-
tained throughout the study.Statistical analysis
For the purpose of data analyses, ICTs were
grouped into 3 categories:20
1) one-to-one (dialogic): e-mail, Skype, SMS, and
WhatsApp.
2) one-to-many (informative): blogs or forums,
YouTube, and web browsers.
3) many-to-many (social): Facebook, Instagram,
LinkedIn, and Twitter.
In addition, the interest scale was dichotomized
as “very-to-extremely interested” (very interested
and extremely interested) and “not very-to-
moderately interested” (not interested, slightly
interested, and moderately interested).
A binomial logistic regression analysis was per-
formed to predict the likelihood of participants
being very to extremely interested or not in
receiving information, asking physicians questions,
and communicating with other patients through
any ICT category given the effects of age, gender,
education level, geographic area, and years
following diagnosis. All data were analyzed using
SPSS version 24.0 software (SPSS Inc., Chicago, IL,
USA).RESULTS
Patient population
A total of 1841 urticaria patients were included
with a female/male gender distribution ratio of
2.31 and a mean age of 40.7 years (Table 1). Most
patients (81.8%) had CSU, and 36.6% had CIndU
(18.6% had both). Most patients had either an
undergraduate degree (35.1%) or secondary
school diploma (32.0%), and half were employed
(50.3%). In addition, most participants were
Europeans (50.7%), followed by Latin Americans
(26.5%) and Asians (22.8%) (Supplemental
Table S1).
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receive information about their disease and in
communicating with physicians and other CU
patients
Approximately, 9 of 10 patients (87.3%) were
interested in the use of ICTs to receive CU in-
formation; most were also interested in the use
of ICTs to ask physicians about CU (84.1%) and
to communicate with other patients (65.6%).CU patients prefer the use of web browsers to
receive information about their disease
One-to-many (50.7%) and one-to-one (51.5%)
were the preferred ICT categories for CU patients
who were very/extremely interested in receiving



























Table 1. Demographic and clinical information of surveyed population
SD, standard deviationWeb browsers were the highest rated ICT for
this purpose, with 44.5% of patients being very or
extremely interested in their use for receiving CU
information.
Only 21.5% of CU patients were very or
extremely interested in the use of many-to-many
ICTs for this purpose. In fact, 60.4% of patients
were not interested at all in the use of many-to-
many ICTs to obtain CU information. Living in ru-
ral areas, and higher education presented higher
odds of being interested to receive information
through every ICT type (Table 3, Supplemental
Table S2, and S4A-S4B). ICT category prefer-
ences for receiving CU information by country are






















. CIndU ¼ chronic inducible urticaria; CSU ¼ chronic spontaneous urticaria;
Volume 14, No. 6, Month 2021 5CU patients prefer the use of e-mail to ask physi-
cians about urticaria
Most CU patients preferred one-to-one ICTs for
asking physicians about urticaria (57.6%; Fig. 1). E-
mail was the highest rated ICT for this purpose with
33.8% of patients being very or extremely
interested in its use, followed by web browsers
with 28.7%.
Again, living in rural areas and higher education
were drivers of high levels of interest in the use of
all ICT categories for asking physicians about ur-
ticaria (Table 3, Supplemental S4A-S4B, S5).
Country-specific ICT category preferences for this
purpose are shown in Supplemental Table S6.CU patients prefer the use of WhatsApp for ICT-
based communication with other patients
One-to-one was the preferred ICT category of
CU patients who were very or extremely interested
in communicating with other patients (33.0%;
Fig. 1).WhatsApp was the highest rated ICT for this
purpose with 24.8% of patients being very or
extremely interested in its use for communicating
with other patients, followed by web browsers
with 19% (Table 2).
Interest in using almost all ICT categories for
communication with other CU patients was driven,
again, by rural living and higher education
(Table 3, Supplemental Table S4A-S4B, S7).
Supplemental Table S8 shows country-specificFig. 1 Frequencies of patients being “very to extremely interested” or “n
asking, and receiving information about urticaria through each ICT cat
many-to-many ICTs (Facebook, Instagram, LinkedIn, and Twitter), one-to
one (e-mail, Skype, SMS, and WhatsApp)preferences for ICT category use for communi-
cating with patients.DISCUSSION
Previously, we reported that almost all CU pa-
tients have access to ICTs and most use these
regularly for health and disease-related informa-
tion.19 Here, we found that most patients with CU
were interested in the use of ICTs for receiving
information, asking physicians, and
communicating with other patients about
urticaria. Of note, patients prefer different ICTs
for these 3 purposes: web browsers for obtaining
information; email for asking physicians; and
WhatsApp for communicating with other patients.Obtaining information
Almost all CU patients used ICTs for obtaining
health and disease-related information.19 One-to
many ICTs, specifically web browsers were most
frequently used, and the high usage of web
browsers by >75% of patients was consistent with
other chronic diseases.16,21 Interestingly, one-to-
one ICTs such as email and WhatsApp were also
held to be of high interest to patients who are
looking for information on their urticaria. Fewer
patients use email and WhatsApp compared to
web browsers; this may indicate a lack of infor-
mation initiatives for these ICTs with a residual
need to develop them.ot interested” at all in communicating with other urticaria patients,
egory. ICT ¼ Information and communication technologies. Note:
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19 (1.0%) 91 (4.9%) 90 (4.9%) 76 (4.1%)
LinkedIn 1711
(92.9%)
18 (1.0%) 22 (1.2%) 35 (1.9%) 10 (0.5%)
Twitter 1669
(90.7%)




12 (0.7%) 81 (4.4%) 91 (4.9%) 79 (4.3%)
Web browser 600
(32.6%)
















27 (1.5%) 32 (1.7%) 31 (1.7%) 15 (0.8%)
SMS 1221
(66.3%)





22 (1.2%) 156 (8.5%) 294
(16.0%)
231 (12.5%)










15 (0.8%) 75 (4.1%) 78 (4.2%) 44 (2.4%)
LinkedIn 1717
(93.3%)
7 (0.4%) 54 (2.9%) 13 (0.7%) 7 (0.4%)
Twitter 1694
(92.0%)




12 (0.7%) 83 (4.5%) 87 (4.7%) 54 (2.9%)
Web browser 868
(47.1%)





14 (0.8%) 161 (8.7%) 83 (4.5%) 54 (2.9%)
(continued)





















27 (1.5%) 71 (3.9%) 63 (3.4%) 32 (1.7%)
SMS 1227
(66.6%)





21 (1.1%) 182 (9.9%) 390
(1.2%)
325 (17.7%)
Interest in communicating with other









26 (1.4%) 66 (3.6%) 61 (3.3%) 54 (2.9%)
LinkedIn 1724
(93.6%)
10 (0.5%) 31 (1.7%) 27 (1.5%) 6 (0.3%)
Twitter 1691
(91.9%)























35 (1.9%) 52 (2.8%) 59 (3.2%) 21 (1.1%)
SMS 1321
(71.8%)
17 (0.9%) 182 (9.9%) 97 (5.3%) 74 (4.0%)
WhatsApp 1083
(58.8%)
25 (1.4%) 204 (11.1%) 253
(13.7%)
204 (11.1%)
Table 2. (Continued) Distribution of participants per degree of interest in using individual ICTs for health-related purposes. ICT ¼ nformation
and communication technologies; SMS ¼ short message service. Notes: Due to missing data in some answers, adding up the percentages for specific ICTs or
categories may not add up to 100%
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Email is a unique one-to-one addition to the
conventional methods of consultation, one which
improves communication and enhances manage-
ment of chronic diseases.22 In chronic diseases,
when patients were asked which ICTs they preferfor asking physicians questions about their disease,
e-mail was consistently rated very high.23,24 In
multiple studies, young and highly educated
patients were more interested in using email to
communicate with their HCPs.25,26 Our findings




ICT type OR (95% CI)
Interest in asking
physicians about urticaria
through ICT type OR (95%
CI)
Interest in communicating
with other patients through
ICT type OR (95% CI)
Many-to-many
Age 0.98 (0.97–0.98) 0.97 (0.97–0.98) 0.96 (0.95–0.97)
Living area




2.25 (1.34–3.79) 1.65 (0.99–2.75) 1.63 (0.96–2.75)
Postgraduate
studies
1.97 (1.14–3.39) 1.36 (0.80–2.34) 1.81 (1.05–3.13)
One-to-Many
Age 0.98 (0.97–0.98) 0.99 (0.98–0.99) 0.97 (0.97–0.98)
Years with urticaria 1.03 (1.01–1.05) 1.00 (0.98–1.02) 1.00 (0.99–1.03)
Living area




2.74 (1.84–4.01) 2.00 (1.28–3.13) 2.22 (1.32–3.72)
Undergraduate/
college
4.18 (2.80–6.23) 2.90 (1.87–4.51) 3.18 (1.91–5.30)
Postgraduate
studies
2.39 (1.58–3.62) 1.93 (1.22–3.07) 2.36 (1.38–4.03)
One-to-One
Age 0.99 (0.98–0.99) 0.99 (0.98–0.99) 0.99 (0.98–0.99)
Living areaa




2.36 (1.60–3.47) 2.05 (1.41–2.97) 1.71 (1.14–2.67)
Undergraduate/
college
3.45 (2.34–5.08) 3.59 (2.47–5.23) 2.02 (1.32–3.08)
Postgraduate
studies
2.34 (1.57–3.49) 3.02 (2.04–4.47) 2.21 (1.43–3.42)
Table 3. Characteristics of ICT users reporting to be very or extremely interested in receiving urticaria information, asking physicians about
urticaria and communicating with other urticaria patients through ICT type. Notes many-to-many ICTs (Facebook, Instagram, LinkedIn and Twitter),
one-to-many (blogs or forums, YouTube and web browsers), and one-to-one (e-mail, Skype, SMS and WhatsApp). Regression analyses were adjusted for
variables such as age, gender, education level, living area and years with urticaria. Bolded values are significant at 0.05 significance level. OR, odds ratio; CI,
confidence interval a. Reference living area is “rural” b. Reference education level category is “No education/Primary school”
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WhatsApp is the most popular global mobile
messenger application and is cost-effective, fast,
reliable, and easy to use. In a literature review,
WhatsApp was shown to be an effective tool for
both communication and learning between HCPs
and the general public.27 Many physicians have
incorporated WhatsApp into their everyday
practice, given its practical advantages.28
Moreover, at UCARE centers, we have observed
a 50% increase in the usage of WhatsApp
during the COVID-19 pandemic in our clinics.19
It is the second most frequently used ICT
following cell phones.19 In our study, WhatsApp
rated very high for communication with other
CU patients. This information may help patient
organizations to make use of this ICT in
connecting CU patients.Usage of ICTs among different groups
Usage of ICTs differed depending on age, living
area, and educational level. Younger age was a
significant predictor of high interest (very/
extremely) in the usage of every ICT type for the 3
specific purposes studied. Similar results have
been reported where younger generations had the
highest overall ICT usage compared to older
cohorts.17
We expected lower levels of ICT usage in
countries that were highly regulated such as Iran;
however, we found that Argentina had lower us-
age, too. Given limited access to specialists in rural
areas, ICTs could be useful, especially in devel-
oping countries where there is evidence that ICT
usage helps to prevent disease.29
Predictably, higher levels of education were
associated with increased ICT usage for the 3 areas
studied. While data suggest women use social
networks more than men,30 we did not find any
difference in ICT usage between genders even
though the prevalence of CU is higher in women,
which was confirmed by our results.The future
Results here support the development of vali-
dated disease content for easy-to-use ICTs that are
CU-specific, focus on one-to-one and one-to-many
communication, and include patient-reportedoutcomes to help assess disease severity and
course, particularly during the current pandemic.
New ICTs should be user friendly. Techno-
complexity has negative consequences and
would ultimately lead to nonadherence and
greater stress in all age groups, particularly the
elderly.31 In all, new ICTs could provide patients
with optimized, tailored disease information and
communications which would ultimately improve
CU management and outcomes.
Strengths and limitations
Our study included participants of different
ages, genders, and education levels across many
regions. Moreover, our network had the capacity
to obtain a high sample globally. However, there
were study limitations. The study design was cross-
sectional and therefore cause-and-effect relation-
ships could not be detected. Our 23-item survey
has not been validated. Participants knew the
purpose of this study in advance. In addition,
accessibility of ICTs varies between countries.
Given the high rate of EU participants, differences
between countries/continents could not be
detected. Randomized trials are necessary to
determine the efficacy and cost effectiveness of
new ICT tools in promoting CU control as well as
providing sources of information about disease
and self-management.CONCLUSIONS
While a number of ICT types have become
universal in modern medical practice, the results of
our study demonstrated that one-to-one and one-
to-many ICTs were the most preferred types for CU
patients to receive disease information and to
communicate with their physicians and other pa-
tients. Urticaria specialists and accredited centers
could, in coordination with ICT designers, intro-
duce personalized technological solutions for each
patient. Additionally, feedback loops could be in-
tegrated to improve tailoring and allow content to
be adapted to changing needs.Abbreviations
ICT: information and communication technologies; CU:
chronic urticaria; CSU: chronic spontaneous urticaria;
CIndU: chronic inducible urticaria; HCP: healthcare
providers; SMS: short message service.
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